Drug Combinations: Mathematical Modeling and Networking Methods

Abstract

Treatments consisting of mixtures of pharmacological agents have been shown to have superior effects to treatments involving single compounds. Given the vast amount of possible combinations involving multiple drugs and the restrictions in time and resources required to test all such combinations in vitro, mathematical methods are essential to model the interactive behavior of the drug mixture and the target, ultimately allowing one to better predict the outcome of the combination. In this review, we investigate various mathematical methods that model combination therapies. This survey includes the methods that focus on predicting the outcome of drug combinations with respect to synergism and antagonism, as well as the methods that explore the dynamics of combination therapy and its role in combating drug resistance. This comprehensive investigation of the mathematical methods includes models that employ pharmacodynamics equations, those that rely on signaling and how the underlying chemical networks are affected by the topological structure of the target proteins, and models that are based on stochastic models for evolutionary dynamics. Additionally, this article reviews computational methods including mathematical algorithms, machine learning, and search algorithms that can identify promising combinations of drug compounds. A description of existing data and software resources is provided that can support investigations in drug combination therapies. Finally, the article concludes with a summary of future directions for investigation by the research community.

Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice

“…NF-κB/AP-1 activity (NF-κB/AP-1-dependent SEAP reporter gene expression) in RAW-Blue cells (Invivogen, San Diego, CA, USA) treated for 18 h with the indicated doses (μg/mL) of MDP and MPLA (alone or in combination). Mathematical modeling of synergy was performed basing on previously published method [ 42 ] (A) Bars represent a mean fold increase ± SD (error bars) in SEAP activity relative to intact (untreated) cells (values are mean from three independent experiments, each performed in duplicate). Asterisks indicate significant differences ( p < 0.05) in SEAP activity between treatment with a combination of PRR agonists and the sum of the activity levels seen in cells treated with MPLA and MDP alone.…”

Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen

“…The ability to evaluate the effective drug combinations using a multitude of experiments in complex and context-dependent cancer is a very daunting task. The mechanistic understanding of the drug suppression when used alone, as well as in relationships with other drugs, is another systematic challenge, and a third challenge is the statistical assessment of the synergies as different models can be implemented in combination experiments [40,58,59]. Fewer studies have been conducted at a large scale to determine the potential synergistic drug combinations [60][61][62].…”

Verification of a Novel Approach to Predicting Effects of Antibiotic Combinations: In Vitro Dynamic Model Study with Daptomycin and Gentamicin against Staphylococcus aureus

“…The Bliss independence principle was used to analyze the daptomycin–gentamicin interaction, assuming that the drugs do not interact with each other when used in combination [ 47 , 48 , 49 ]. Bliss independence is described by the equation: E IND = E D + E G − E D × E G where E IND is the expected anti-staphylococcal effect of daptomycin–gentamicin combinations calculated using the effects of respective mono-treatments with daptomycin ( E D ) and gentamicin ( E G ).…”